SAB Biotherapeutics, Inc.SABSEarnings & Financial Report
SAB Biotherapeutics is a clinical-stage biopharmaceutical company that develops novel fully human polyclonal antibody therapies leveraging its proprietary transchromosomic cattle platform. Its product pipeline targets unmet medical needs across infectious diseases, autoimmune conditions, and oncology, serving global patient populations.
Revenue
$263.1K
Gross Profit
N/A
Operating Profit
$-10.2M
Net Profit
$-7.3M
Gross Margin
N/A
Operating Margin
-3877.0%
Net Margin
-2787.7%
YoY Growth
207.7%
EPS
$-0.79
SAB Biotherapeutics, Inc. Q2 FY2024 Financial Summary
SAB Biotherapeutics, Inc. reported revenue of $263.1K (up 207.7% YoY) for Q2 FY2024, with a net profit of $-7.3M (down 6.6% YoY) (-2787.7% margin).
Key Financial Metrics
| Total Revenue | $263.1K |
|---|---|
| Net Profit | $-7.3M |
| Gross Margin | N/A |
| Operating Margin | -3877.0% |
| Report Period | Q2 FY2024 |
SAB Biotherapeutics, Inc. Annual Revenue by Year
SAB Biotherapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $2.2M).
| Year | Annual Revenue |
|---|---|
| 2023 | $2.2M |
| 2022 | $23.9M |
SAB Biotherapeutics, Inc. Quarterly Revenue & Net Profit History
SAB Biotherapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2024 | $0 | — | $-10.3M | N/A |
| Q2 FY2024 | $263.1K | +207.7% | $-7.3M | -2787.7% |
| Q1 FY2024 | $944.6K | +62.5% | $-5.0M | -532.1% |
| Q4 FY2023 | $305.0K | -85.9% | N/A | N/A |
| Q3 FY2023 | $1.3M | -64.7% | $-5.1M | -402.6% |
| Q2 FY2023 | $85.5K | -98.7% | $-6.9M | -8046.1% |
| Q1 FY2023 | $581.1K | -95.1% | $-7.4M | -1265.5% |
| Q4 FY2022 | $2.2M | -80.5% | $-7.9M | -364.4% |
Income Statement
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $581101 | $85518 | $1.3M | $305011 | $944575 | $263137 | $0 |
| YoY Growth | -80.5% | -95.1% | -98.7% | -64.7% | -85.9% | 62.5% | 207.7% | N/A |
Balance Sheet
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $50.9M | $42.7M | $35.4M | $28.3M | $83.9M | $71.4M | $61.9M | $53.8M |
| Liabilities | $19.8M | $18.3M | $15.7M | $13.1M | $26.6M | $18.5M | $15.8M | $16.9M |
| Equity | $31.1M | $24.4M | $19.7M | $15.3M | $57.3M | $52.8M | $46.1M | $36.9M |
Cash Flow
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.6M | $-1.6M | $-4.9M | $-5.2M | $-25.1M | $-10.8M | $-7.7M | $-6.3M |